The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—General
Hunan Jingfeng Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% CNY1.690
America/New_York / 29 apr 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 486.82 mill |
| EPS: | -0.150 |
| P/E: | -11.27 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 879.77 mill |
| Avg Daily Volume: | 57.35 mill |
| RATING 2024-04-29 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -11.27 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -11.27 | industry: PE 55.30 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY-0.905 (-153.56%) CNY-2.60 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
CNY 1.498 - 1.882 ( +/- 11.36%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY1.690 (0.00% ) |
| Volume | 42.83 mill |
| Avg. Vol. | 57.35 mill |
| % of Avg. Vol | 74.68 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 000908.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
000908.SZ
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. The company was founded in 2003 and is headquartered in Shanghai, China.